|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00512 GRAND PHARMA
Nominal 
5.240 -0.020 (-0.380%) | 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Turnover | 6,388,913 | 3.227% | 12,283,271 | 11,644,892 | 10,529,590 | 9,562,285 |
| Cost of Sales | (3,021,240) | 19.127% | (5,502,910) | (4,906,576) | (4,005,524) | (3,610,806) |
| Gross Profit | 3,367,673 | -7.812% | 6,780,361 | 6,738,316 | 6,524,066 | 5,951,479 |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 114,376 | -34.490% | (189,313) | 599,472 | 18,763 | (91,345) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (38,718) | (73,378) | (58,664) | 23,017 | |
| Share of Results of Asso. & JCEs | 58,314 | 0.639% | 76,059 | 148,720 | (25,008) | (43,786) | |
| Profit / (Loss) before Taxation | 1,258,081 | -9.103% | 1,494,081 | 2,852,363 | 2,344,197 | 2,516,893 | |
| Taxation | (189,475) | 4.816% | (249,778) | (386,304) | (448,755) | (418,642) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (7,068) | -30.255% | (3,432) | 2,316 | (15,444) | (18,832) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,061,538 | -11.032% | 1,240,871 | 2,468,375 | 1,879,998 | 2,079,419 | |
| 2026/06 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/12 HKD(K$) | 2024/12 HKD(K$) | 2023/12 HKD(K$) | 2022/12 HKD(K$) | |
| Net Finance Costs / (Income) | 76,756 | -6.389% | 154,970 | 173,932 | 197,400 | 117,687 |
| Depreciation & Amortisation | 349,495 | 18.473% | 581,895 | 503,748 | 392,210 | 394,912 |
| Directors' Emoluments | -- | -- | 7,507 | 5,900 | 8,988 | 6,357 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 30.310 | -11.036% | 35.440 | 70.490 | 53.600 | 58.700 |
| DPS (cts) | 0.000 | -- | 16.900 | 26.000 | 26.000 | 14.000 |
| Dividend Payout Ratio (%) | -- | -- | 47.686% | 36.885% | 48.507% | 23.850% |
| Cash flow per share ($) | -- | -- | 0.471 | 0.542 | 0.691 | 0.520 |
| NBV per share ($) | 4.862 | -- | 4.794 | 4.641 | 4.270 | 3.984 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 1,061,538 |
| %Change | -11.032% |
| EPS / (LPS) | HKD 0.303 |
| NBV Per Share ($) | HKD 4.862 |